Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
- PMID: 27036043
- PMCID: PMC5053692
- DOI: 10.18632/oncotarget.8425
Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
Abstract
The PET Response Criteria in Solid Tumors (PERCIST) is a new method for the quantitative assessment of metabolic changes in solid tumors. The assessments of tumor response between the RECIST and PERCIST have shown considerable difference in several studies. This pooled study was conducted to compare tumor response according to the two criteria in patients with solid tumors. We surveyed MEDLINE, EMBASE and PUBMED for articles with terms of the RECIST or PERCIST from 2009 and January 2016. There were six articles comparing the RECIST and PERCIST. A total of 268 patients were recruited; 81 with colorectal cancer, 60 with lung cancer, 48 with esophageal cancer, 28 with breast cancer, 14 with basal cell carcinoma, 12 with stomach cancer, 10 with head and neck cancer, and 16 with other rare cancers. The agreement of tumor response between the RECIST and PERCIST was moderate (k = 0.590). Of 268 patients, 101 (37.7%) showed discordance in the tumor responses between two criteria. When adopting the PERCIST, tumor response was upgraded in 85 patients and downgraded in 16. The estimated overall response rates were significantly different between two criteria (35.1% by RECIST vs. 54.1% by PERCIST, P < 0.0001). In conclusion, this pooled analysis demonstrates that the concordance of tumor responses between the RECIST and PERCIST criteria is not excellent. The PERCIST might be more suitable for assessing tumor response than the RECIST criteria.
Keywords: PERCIST; PET; RECIST 1.0; RECIST 1.1; tumor response.
Conflict of interest statement
Authors declare no conflict of interest.
Similar articles
-
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.Eur J Radiol. 2018 Apr;101:65-71. doi: 10.1016/j.ejrad.2018.02.009. Epub 2018 Feb 13. Eur J Radiol. 2018. PMID: 29571803
-
Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.Korean J Intern Med. 2019 May;34(3):608-617. doi: 10.3904/kjim.2017.063. Epub 2018 Jan 17. Korean J Intern Med. 2019. PMID: 29334722 Free PMC article.
-
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.Cancer Chemother Pharmacol. 2017 Oct;80(4):729-735. doi: 10.1007/s00280-017-3411-9. Epub 2017 Aug 5. Cancer Chemother Pharmacol. 2017. PMID: 28780726 Review.
-
Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review.Oncotarget. 2016 Sep 6;7(36):58105-58110. doi: 10.18632/oncotarget.11171. Oncotarget. 2016. PMID: 27517621 Free PMC article. Review.
-
Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1945-53. doi: 10.1007/s00259-016-3420-7. Epub 2016 May 28. Eur J Nucl Med Mol Imaging. 2016. PMID: 27236466 Clinical Trial.
Cited by
-
CT-guided radioactive 125I seeds brachytherapy for lung oligometastases from colorectal cancer: initial results.BMC Cancer. 2024 Feb 26;24(1):265. doi: 10.1186/s12885-024-12013-2. BMC Cancer. 2024. PMID: 38403626 Free PMC article.
-
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.Melanoma Res. 2024 Apr 1;34(2):166-174. doi: 10.1097/CMR.0000000000000952. Epub 2023 Dec 19. Melanoma Res. 2024. PMID: 38126339 Free PMC article.
-
From RECIST to PERCIST: navigating the landscape of tumor response assessment.Eur Radiol. 2024 Jun;34(6):3656-3658. doi: 10.1007/s00330-023-10435-3. Epub 2023 Nov 13. Eur Radiol. 2024. PMID: 37955672 No abstract available.
-
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.J Immunother Cancer. 2023 Oct;11(10):e007444. doi: 10.1136/jitc-2023-007444. J Immunother Cancer. 2023. PMID: 37865397 Free PMC article. Clinical Trial.
-
Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology.Explor Target Antitumor Ther. 2023;4(4):569-582. doi: 10.37349/etat.2023.00153. Epub 2023 Aug 24. Explor Target Antitumor Ther. 2023. PMID: 37720353 Free PMC article. Review.
References
-
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version1. 1) Eur J Cancer. 2009;45:228–47. - PubMed
-
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. - PubMed
-
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14. - PubMed
-
- Liu Y, Litiëre S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014;50:260–6. - PubMed
-
- Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P. RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009;45:248–60. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources